Dr. Frances Shepherd CV - (NCRI) is
Dr. Frances Shepherd CV - (NCRI) is
Dr. Frances Shepherd CV - (NCRI) is
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
58. Anraku M, Waddell TK, de Perrot M, Lwe<strong>is</strong> SJ, Pierre AF, Darling GE, Johnston MR, Zener<br />
RE, Rampersaud YR, <strong>Shepherd</strong> FA, Leighl N, Bezjak A, Sun AY, Hwang DM, Tsao MS,<br />
Keshavjee S. Induction chemoradiotherapy facilitates radical resection of T4 non-small cell<br />
lung cancer invading the spine. J Thorac Oncol. 2009 Feb; 137: 441-447.<br />
59. Boutros PC, Lau Sk, Pintilie M, Liu N, <strong>Shepherd</strong> FA, Der SD, Tsao MS, Penn LZ, Jur<strong>is</strong>ica I.<br />
Prognostic gene signatures for non-small cell lung cancer. Proc Natl Acad Sci U S A. 2009<br />
Feb 5.<br />
60. Ell<strong>is</strong> PM, Morzycki W, Melosky B, Butts C, Hirsh V, Krasnoshtein F, Murray N, <strong>Shepherd</strong><br />
FA, Soulieres D, Tsao MS, Goss G. The role of the epidermal growth factor receptor tyrosine<br />
kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small cell lung cancer:<br />
a Canadian national consensus statement. Curr Onc. 2009 16: 25-46.<br />
61. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, <strong>Shepherd</strong><br />
FA. The differential efficacy of pemetrexex according to NSCLC h<strong>is</strong>tology: a review of two<br />
phase III studies. Oncolog<strong>is</strong>t 2009 Mar 14: 253-63.<br />
62. Gauthier LR, Rodin G, Zimmerman C, Warr D, Moore M, <strong>Shepherd</strong> FA, Gagliese L.<br />
Acceptance of pain: a study in patients with advanced cancer. Pain 2009 May 143: 147-54.<br />
63. Le Maitre A, Ding K, <strong>Shepherd</strong> FA, Leighl N, Arnold A, Seymour L, NCIC Clinical trials<br />
Group. Anticoagulation and bleeding; a pooled analys<strong>is</strong> of lung cancer trials of the NCIC<br />
Clinical Trials Group. J Thoracic Oncol. 2009 May: 4: 586-94.<br />
64. Roberts HC, Patsios DA, Paul NS, dePerrot M, Teel W, Bayanati H, <strong>Shepherd</strong> FA, Johnston<br />
MR. Screening for malignant pleural mesothelioma and lung cancer in individuals with a<br />
h<strong>is</strong>tory of asbestos exposure. J Thoracic Cardiovascular Surg, 2009 Oct 138:843-8.<br />
65. Menezes RJ, Roberts HC, Paul NS, McGregor M, Chung TB, Patsios D, We<strong>is</strong>brod G, Herman<br />
S, Pereira A, McGregor A, Dong Z, Sitartchuk I, Boerner S, Tsao MS, Keshavjee S,<br />
<strong>Shepherd</strong> FA. Lung cancer screening using low-dose computed tomography in at-r<strong>is</strong>k<br />
individualsL The Toronto experience. Lung Cancer 2009; 67,177-83.<br />
66. Soria JC, <strong>Shepherd</strong> FA, Douillard JY, Wolf J, Giaccone G, Crino L, Capuzzo F, Sharma S,<br />
Gross Sh, Dimitrijevic S, Di Scala L, Gardner H, Nogova L, Papadimitrakopoulo V. Efficacy<br />
of everolimus (RAD001) in patients with advanced NSCLC previously treated with<br />
chemotherapy and EGFR inhibitors. Ann Oncol. 2009 Oct 20: 1674-81.<br />
67. Bradbury PA, Kulke MH, He<strong>is</strong>t RS, Zhou W, Ma C, Xu W, Marshall Al, Zhai R, Hooshmand<br />
SM, Asomaning K, Su L, <strong>Shepherd</strong> FA, Lynch TJ, Wain JC, Chr<strong>is</strong>tiani DC, Liu G. C<strong>is</strong>platin<br />
pharmacogenetics, DNA repair polymorph<strong>is</strong>ms, and esophageal cancer outcomes.<br />
Pharmacogenet Genomics. 2009 Aug: 613-25.<br />
68. Wheatley-Price P, Massey C, Panzarella T, <strong>Shepherd</strong> FA, Mikhael J. Resident preparedness in<br />
d<strong>is</strong>cussing prognos<strong>is</strong> in patients with advanced lung cancer. Support Care Cancer. 2009 Jul 21.<br />
69. Albain KS, Swann RS, Rush VW, Turr<strong>is</strong>i AT 3 rd , <strong>Shepherd</strong> FA, Smith C, Chen Y, Livingston<br />
RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J,<br />
Sause WT, Cox JD. Radiotherapy plus chemotherapy with or without surgical resection die stage<br />
III non-small cell lung cancer: a phase III randomized controlled trial. Lancet 2009 Aug 1: 379-<br />
86.<br />
70. Lynch TJ, Fenton D, Hirsh V, Bodkin D, Middleman EL, Chiappori A, Halmos B, Fav<strong>is</strong> R, Liu<br />
H, Trepicchio WL, Eton O, <strong>Shepherd</strong> FA. A randomized phase 2 study of erlotinib alone and in<br />
combination with bortezomib in previously treated advanced non-small cell lung cancer. J<br />
Thoracic Oncol. 2009 Aug 4: 1002-9.<br />
71. Vallieres E, <strong>Shepherd</strong> FA, Crowley J, Van Houtte P. Postmus PE, Carney D, Chansky K, Shaikh<br />
Z, Goldstraw P, International Association for the Study of Lung Cancer international Staging<br />
Committee and Participating Institutions. The IASLc Cancer Staging Project: proposals regarding<br />
the revelance of TNM in the pathologic staging of non-small cell lung cancer in the forthcoming<br />
(seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2009 Sep 4: 1049-<br />
59.<br />
10
Change language